Welcome to our dedicated page for Impel Pharmaceuticals news (Ticker: IMPL), a resource for investors and traders seeking the latest updates and insights on Impel Pharmaceuticals stock.
Impel Pharmaceuticals Inc. (symbol: IMPL) is a Seattle-based biopharmaceutical company dedicated to providing groundbreaking therapies for central nervous system (CNS) diseases. Their innovative approach leverages a proprietary nasal drug delivery system known as the POD™ device, which ensures consistent and predictable drug administration to the upper nasal cavity.
Impel's diverse product portfolio is focused on addressing significant unmet medical needs.
- INP104 (POD™ DHE) is in development for the acute treatment of migraine headaches.
- INP103 (POD™ Levodopa) aims to offer relief for Parkinson's disease patients.
- INP105 (POD™ Olanzapine) targets agitation associated with schizophrenia and bipolar disorders.
- INP102 (POD™ Insulin) is being tested in an NIH-funded trial for Alzheimer's disease.
In September 2021, Impel received FDA approval for Trudhesa®, a nasal spray specifically designed for the acute treatment of migraine with or without aura in adults. This marks a significant milestone in their journey to provide effective therapies for CNS conditions.
Despite recent achievements, Impel has encountered financial challenges and has filed for Chapter 11 bankruptcy as part of a strategic decision to maximize value for stakeholders. The company is actively pursuing a sale and has entered into an agreement with JN BIDCO LLC as the 'stalking horse' bidder. Throughout this process, Impel aims to continue operating normally, ensuring minimal disruption to its customers, employees, and other key stakeholders.
For more details, visit Impel Pharmaceuticals Inc.
Impel NeuroPharma (NASDAQ: IMPL) announced new data indicating that Trudhesa (dihydroergotamine mesylate) nasal spray offers rapid and consistent relief for migraine sufferers. Scheduled poster presentations at the American Academy of Neurology annual meeting (April 2-7, 2022) will detail the pivotal Phase 3 STOP-301 trial outcomes, demonstrating Trudhesa's effectiveness even after prior acute therapies. The findings suggest significant reductions in migraine frequency and disability, highlighting the need for more effective acute treatment options in the migraine market.
Impel NeuroPharma (NASDAQ: IMPL) will host a live webcast on March 24, 2022, at 8:30 a.m. ET to discuss its fourth quarter and full year 2021 financial results. The company focuses on developing therapies for high unmet medical needs, especially in central nervous system diseases. Impel's current offerings include Trudhesa™, an approved nasal spray for migraine treatment, and ongoing development of INP105 for autism-related agitation and INP107 for Parkinson’s OFF episodes. The webcast will be accessible via the Investor section of their website.
Impel NeuroPharma (NASDAQ: IMPL) announced a $100 million financing agreement with Oaktree Capital Management to support the commercialization of Trudhesa™, extending its cash runway into 2024. The deal includes a $50 million royalty agreement based on U.S. sales of Trudhesa™ and a $50 million senior secured debt. The royalty structure features tiered payments capped at 1.75x the upfront amount. This transaction is expected to bolster the company's balance sheet and enhance growth potential for Trudhesa™, a nasal spray for migraine treatment.
Impel NeuroPharma (NASDAQ: IMPL) announced that CEO Adrian Adams will participate in two upcoming investor conferences. The Cowen & Co. 42nd Annual Health Care Conference will feature a fireside chat on March 7, 2022, at 1:30 p.m. ET, while the Oppenheimer 32nd Annual Healthcare Conference will include a company presentation on March 17, 2022, at 2:40 p.m. ET. Investors can access a live webcast and a 90-day replay on the company's website. Impel specializes in therapies for high unmet medical needs, focusing on the central nervous system.
Impel NeuroPharma reported a successful Q4 2021 launch of Trudhesa™, generating over 4,200 prescriptions, exceeding guidance of 3,000-4,000. The company achieved contracts with pharmacy benefit managers, covering 80% of U.S. commercial lives. They anticipate the initiation of the INP105 study for Autism Spectrum Disorder in Q1 2022, with results expected in Q4 2022. Impel's focus on central nervous system diseases is supported by a robust pipeline and innovative POD® delivery technology. This performance positions Impel for growth in the competitive migraine treatment market.
Impel NeuroPharma (NASDAQ: IMPL) launched Trudhesa™ nasal spray for acute migraine treatment, reporting its Q3 2021 results. The FDA approved Trudhesa on September 3, and initial sales of $0.1 million were recognized before its commercial launch on October 4. The company completed a follow-on equity offering, raising $51.8 million from the sale of 3.45 million shares, extending its financial runway. R&D expenses decreased to $5.9 million, while SG&A expenses surged to $16.3 million. Impel reported a GAAP net loss of $25.0 million, up from $9.2 million year-over-year.
Impel NeuroPharma (NASDAQ: IMPL) will have its Chairman and CEO, Adrian Adams, participate in a fireside chat during the Guggenheim Securities 3rd Annual Neuro/Immunology Conference on November 16, 2021, at 1:40 p.m. ET. A live webcast will be available on the company’s investor website, with a replay accessible afterward. Impel NeuroPharma focuses on developing innovative therapies for central nervous system diseases, including the approved Trudhesa™ for migraines and ongoing development of INP105 and INP107 for autism-related agitation and Parkinson’s OFF episodes.
Impel NeuroPharma (NASDAQ: IMPL) will host a live webcast on November 15, 2021, at 8:30 a.m. ET, to discuss its Q3 2021 financial results and provide a business update. The event can be accessed by calling 877-295-2648 (domestic) or 470-495-9487 (international), using conference ID 8366131. The webcast will be available on the company's investor relations website, with a replay and accompanying slides accessible afterward.
Phil, Inc. has partnered with Impel NeuroPharma (NASDAQ: IMPL) to enhance patient access to Trudhesa™, a nasal spray for migraine treatment. This collaboration aims to streamline the distribution process using Phil's technology. Trudhesa is approved for treating acute migraines in adults and utilizes Precision Olfactory Delivery (POD®) Technology for rapid relief. The partnership will enroll eligible patients in a savings program, allowing convenient home delivery without additional costs. Both companies emphasize improving patient outcomes through efficient medication access.
Carepoint Pharmacy has announced a partnership with Impel NeuroPharma to dispense Trudhesa™ (dihydroergotamine mesylate) nasal spray, intended for the acute treatment of migraines. Trudhesa, approved by the FDA on September 2, 2021, utilizes proprietary Precision Olfactory Delivery technology to deliver medication effectively to the bloodstream. As one of two pharmacies in a limited distribution network, Carepoint aims to enhance patient experience with home delivery solutions. Eligible patients benefit from automatic enrollment in a savings program for cost-free medication delivery.
FAQ
What is the market cap of Impel Pharmaceuticals (IMPL)?
What is Impel Pharmaceuticals' core focus?
What is the POD™ device?
What is Trudhesa®?
What are the current products under investigation by Impel?
What recent financial steps has Impel taken?
Who is the 'stalking horse' bidder in Impel's sale process?
Will Impel continue its operations during the sale process?
Who is advising Impel during its restructuring?
Who is Impel's current Chief Restructuring Officer?
How can stakeholders get more information about the proceedings?
